论文部分内容阅读
目的 :建立抗SARS冠状病毒 (SARS_CoV)药物细胞筛选模型 ,应用于抗SARS_CoV药物的筛选 ,为SARS的防治奠定基础。方法 :将一定数量的细胞接种 96孔板 ,根据药物的作用机制采用不同的给药途径 ,以观察到的细胞病变 (cytopathiceffect,CPE)为指标 ,按照Reed_Muench法 ,计算药物的细胞半数中毒浓度 (TD50 )和抑制细胞半数病变的有效浓度 (IC50 )。结果与结论 :Vero_E6细胞接种SARS_CoV后 2 4h即可出现CPE ,且CPE明显 ,便于观察 ,可作为抗SARS病毒药物细胞筛选模型。依此模型筛选了 3类 87种药物 ,确认 6种药物在Vero_E6细胞上具有抑制SARS病毒的作用。该模型的建立也为其他的抗病毒药物的筛选提供了技术平台。
OBJECTIVE: To establish a screening model of anti-SARS coronavirus (SARS-CoV) cell lines and to screen anti-SARS-CoV drugs to lay a foundation for the prevention and treatment of SARS. Methods: A certain number of cells were inoculated into 96-well plates. According to the drug’s mechanism of action, different routes of administration were used. Based on the observed cytopathic effect (CPE) as an indicator, half of the drug concentration was calculated according to the method of Reed_Muench TD50) and half the number of cells to inhibit the effective concentration (IC50). RESULTS AND CONCLUSION: CPE was found in Vero_E6 cells 24 h after inoculation with SARS_CoV, and CPE was obvious and easy to observe. It could be used as a screening model for drug-resistant SARS-virus cells. Three types of 87 drugs were screened based on this model, confirming that the six drugs have the effect of inhibiting SARS virus in Vero_E6 cells. The establishment of this model also provides a technical platform for the screening of other antiviral drugs.